Dataset Information


Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer.

ABSTRACT: We have used a gene expression array-based strategy to identify the methylation of tissue factor pathway inhibitor 2 (TFPI2), a potential tumor suppressor gene, as a frequent event in human colorectal cancers (CRC). TFPI2 belongs to the recently described group of embryonic cell Polycomb group (PcG)-marked genes that may be predisposed to aberrant DNA methylation in early stages of colorectal carcinogenesis. Aberrant methylation of TFPI2 was detected in almost all CRC adenomas (97%, n = 56) and stages I to IV CRCs (99%, n = 115). We further explored the potential of TFPI2 as a biomarker for the early detection of CRC using stool DNA-based assays in patients with nonmetastatic CRC and average-risk noncancer controls who were candidates for screening. TFPI2 methylation was detected in stool DNA from stage I to III CRC patients with a sensitivity of 76% to 89% and a specificity of 79% to 93%. Detection of TFPI2 methylation in stool DNA may act as a useful adjunct to the noninvasive strategies for screening of CRCs in the future.


PROVIDER: S-EPMC3062162 | BioStudies | 2009-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5663576 | BioStudies
1000-01-01 | S-EPMC4396244 | BioStudies
2019-01-01 | S-EPMC6419806 | BioStudies
2020-01-01 | S-EPMC7418412 | BioStudies
1000-01-01 | S-EPMC3883784 | BioStudies
2011-01-01 | S-EPMC3464012 | BioStudies
2017-01-01 | S-EPMC5578878 | BioStudies
2015-01-01 | S-EPMC4687378 | BioStudies
1000-01-01 | S-EPMC3924905 | BioStudies
2017-01-01 | S-EPMC5345264 | BioStudies